Please login to the form below

Not currently logged in
Email:
Password:

CGRP inhibitors

This page shows the latest CGRP inhibitors news and features for those working in and with pharma, biotech and healthcare.

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven gets FDA approval for migraine drug Nurtec ODT

Both the oral CGRP inhibitors have benefited from a collaboration between Allergan and ICER to look at the benefits of ubrogepant beyond the two-hour time point required by the FDA ... A successful outcome in those studies would make the drug a potential

Latest news

  • Lilly launches migraine med Reyvow at $640 per eight-pill pack Lilly launches migraine med Reyvow at $640 per eight-pill pack

    Unlike these antibody-based CGRP inhibitors, which have been approved for migraine prevention and are administered intravenously, Reyvow offers an option for treating attacks once they have already begun. ... Its closest competitor is Allergan’s

  • Allergan gets FDA nod for first oral CGRP drug for migraine Allergan gets FDA nod for first oral CGRP drug for migraine

    Ubrelvy joins a handful of injectable, antibody-based CGRP inhibitors that have been approved for migraine prevention – dosed every few weeks in order to reduce the chances of attacks taking place – ... The CGRP inhibitors offer hope to patients with

  • AbbVie CEO Gonzalez defends Allergan takeover AbbVie CEO Gonzalez defends Allergan takeover

    For AbbVie, Allergan’s most interesting programmes are a clutch central nervous system (CNS) candidates including antidepressant Vraylar (cariprazine) – which it says has blockbuster potential – as well as oral CGRP inhibitors

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    There were also a number of drugs with brand new mechanisms of action, including three CGRP inhibitors for migraine prevention from Amgen, Teva and Eli Lilly – as well as Agios

  • Amgen CEO says Aimovig is “one of most successful launches” Amgen CEO says Aimovig is “one of most successful launches”

    The company estimates that more than 100, 000 patients have taken the Novartis-partnered CGRP inhibitor since its launch in May as a once-monthly, self-injected preventive treatment for migraines. ... The strong take-up has come despite approvals for

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics